Top
Topic: Emerging Trends on the Role of PDGFs and PDGFRs in Health and Disease

A special issue of Vessel Plus

ISSN 2574-1209 (Online)

Submission deadline: 30 Apr 2020

Guest Editor(s)

  • Prof. Shilpa Buch, Ph.D.
    Director- Nebraska Center for Substance Abuse Research
    Community Pride of Nebraska Professorship of Neuroscience
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
    Omaha, NE 68198-5880, USA

    Website | E-mail

  • Dr. Palsamy Periyasmy, Ph.D.
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
    Omaha, NE 68198-5880, USA

    Website | E-mail

  • Dr. Susmita Sil, Ph.D.
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
    Omaha, NE 68198-5880, USA

    Website | E-mail

Special Issue Introduction

Platelet-derived growth factors (PDGFs) belong to a family of mesenchymal cysteine-knot-type mitogens. They are abundantly expressed in several tissues and are known to play vital roles in the formation of blood vessels, proliferation of mesenchymal cells and mesenchymal stem cells, directed migration of mesenchymal cells, wound healing and fibrosis. These biological functions are elicited through binding of these growth factors with their cognate receptors, namely PDGFR-α, and PDGFR-β. Members of the PDGF family play critical roles in both health and disease. It is well-recognized that autocrine PDGF signaling underlies the development of gliomas, sarcomas, and leukemias whereas paracrine PDGF signaling is involved in epithelial cancers, angiogenesis, atherosclerosis, restenosis, pulmonary hypertension, retinal diseases, pulmonary fibrosis, liver cirrhosis, scleroderma, glomerulosclerosis, and cardiac fibrosis, HIV neuropathogenesis and drug abuse. Therapy using PDGF antagonists as well as PDGF receptor-inhibiting substances, has been extensively tested in pre-clinical models as well as in human clinical trials. Despite substantial advances in our understanding of the biology of the members of the PDGF family, its paradoxical roles in normal cellular homeostasis and pathologies necessitate the need to examine their roles in disease and health. The goal of this special issue is to present emerging trends in the roles that PDGF and its receptors play in inflammatory disease processes underlying cardiovascular, cancer, stroke and neurodegenerative processes associated with aging, viral infection and substance abuse with the ultimate aim to pave the way for future therapeutic breakthroughs.

Keywords

PDGF, PDGFR, cancers, angiogenesis, atherosclerosis, pulmonary hypertension, retinal diseases, pulmonary fibrosis, liver cirrhosis, glomerulosclerosis, cardiac fibrosis, HIV neuropathogenesis, drug abuse

Submission Deadline

30 Apr 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://vpjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/vp
Submission Deadline: 30 Apr 2020
Contacts: Mavis Wei, Assistant Editor, editor_12@oaepublish.com

Planned Papers

Type: Original Article

Title: Short-term 5-HT7 receptor activation increases PDGF receptor expression and phosphorylation that is neuroprotective against NMDA-induced excitotoxicity

Authors: Nawaz Ahmed1, Nyasha Gondora1, Maryam Vasefi1, Zahra Razavi1, Michael A. Beazely2, *

Affiliations: 1Department of Biology, Lamar University, Beaumont, TX 77710, USA
2School of Pharmacy, University of Waterloo, 10 Victoria Street South, Kitchener, ON N2G 1C5, Canada

Abstract: Platelet-derived growth factor β receptors (PDGFRβ) are neuroprotective against several neuronal insults. In addition to direct activation of PDGFRβ by its ligand, PDGF-BB, PDGFRβ expression and activity are increased after 5-HT7 receptor activation. Previously, we have shown that long-term (24 h) activation of 5-HT7 receptor protects neurons against glutamate excitotoxicity in a PDGFRβ-dependent manner. Here, we show that 5-HT7-PDGFRβ cross-talk is similarly active over a shorter time-frame, between 2-4 h, in SH-SY5Y cells, primary mouse hippocampal neurons, and hippocampal-derived HT-22 cells.


Type: Review

Title: Neuroprotective Effects of Direct Activation and Transactivation of PDGFbeta Receptors

Authors: Maryam Vasefi1, Michael A. Beazely2, *

Affiliations: 1Department of Biology, Lamar University, Beaumont, TX 77710, USA
2School of Pharmacy, University of Waterloo, 10 Victoria Street South, Kitchener, ON N2G 1C5, Canada

Abstract: Platelet-derived growth factor (PDGF) receptors are expressed throughout the body, including the central nervous system (CNS). Although the physiological role of PDGFbeta receptors in the developed CNS is not fully characterized, its signaling appears to provide neuroprotective effects against several neuronal insults, including ischemic stroke and HIV-associated proteins. PDGFbeta receptors are also neuroprotective against glutamate excitotoxicity, which is associated with neurodegenerative diseases, both via direct activation by ligand (PDGF-BB) as well as by PDGF receptors activated downstream of G protein-coupled receptor signaling. There is emerging evidence that growth factor receptors, including PDGFRs, may play a neuroprotective role in neurological disorders, including Alzheimer’s disease.


Published Articles

This special issue is now open for submission.